☰

Myron N. Chang - Publications

Affiliations: 
University of Florida, Gainesville, Gainesville, FL, United States 
Area:
Statistics, Biostatistics Biology
Tree Info Similar researchers PubMed Report error

37 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2017 Norkin M, Katragadda L, Zou F, Xiong S, Chang M, Dai Y, Hsu JW, Moreb JS, Leather H, Murthy HS, Farhadfar N, Li Y, Hromas R, Brown RA, Cogle CR, et al. Minimal residual disease by either flow cytometry or cytogenetics prior to an allogeneic hematopoietic stem cell transplant is associated with poor outcome in acute myeloid leukemia. Blood Cancer Journal. 7: 634. PMID 29176662 DOI: 10.1038/S41408-017-0007-X  0.349
2016 Katragadda L, McCullough LM, Dai Y, Hsu J, Byrne M, Hiemenz J, May S, Cogle CR, Norkin M, Brown RA, Wingard JR, Chang M, Moreb JS. Effect of Melphalan 140 mg/m(2) versus 200 mg/m(2) on Toxicities and Outcomes in Multiple Myeloma Patients Undergoing Single Autologous Stem Cell Transplantation - A single center experience. Clinical Transplantation. PMID 27219740 DOI: 10.1111/Ctr.12762  0.341
2016 Norkin M, Chang M, An Q, Leather H, Katragadda L, Li Y, Moreb JS, May WS, Brown RA, Hsu JW, Hiemenz JW, Wingard JR, Cogle CR. A new model to predict remission status in AML patients based on day 14 bone marrow biopsy. Leukemia Research. 46: 69-73. PMID 27132034 DOI: 10.1016/J.Leukres.2016.04.013  0.315
2015 Medina C, Drusbosky L, Chang M, Vali S, Kumar A, Singh NK, Abbasi T, Sekeres MA, Mallo M, Sole F, Bejar R, Cogle CR. Predicting MDS Response to Drug Therapies Based on a New Method of Interpreting the MDS Mutanome Blood. 126: 96-96. DOI: 10.1182/Blood.V126.23.96.96  0.327
2015 Katragadda L, Norkin M, Chang M, Dai Y, Moreb JS, May WS, Cogle CR, Leather H, Li Y, Eldjerou LK, Hiemenz JW, Brown RA, Wingard JR. Minimal Residual Disease (MRD) By Either Flow Cytometry or Cytogenetics Prior to an Allogeneic Hematopoietic Cell Transplant (allo-HCT) Predicts Poor Acute Myeloid Leukemia (AML) Outcomes Blood. 126: 3221-3221. DOI: 10.1182/Blood.V126.23.3221.3221  0.334
2015 Katragadda L, McCullough L, Dai Y, Hsu JW, Hiemenz JW, May WS, Cogle CR, Norkin M, Brown RA, Wingard JR, Chang M, Moreb JS. Effect of Melphalan 140 Mg/m2 Versus 200 Mg/m2 on Toxicities and Outcomes in Multiple Myeloma Patients Undergoing Single Autologous Stem Cell Transplantation Blood. 126: 1988-1988. DOI: 10.1182/Blood.V126.23.1988.1988  0.34
2015 Rivera MA, Rajca B, Forsmark CE, Draganov PV, Wagh MS, Gupte A, Chang MN, Dai Y, Chauhan S. Su1597 Predictive Factors for Percutaneous Drainage Placement in Patients Developing Bilomas From Bile Leaks Gastrointestinal Endoscopy. 81. DOI: 10.1016/J.Gie.2015.03.559  0.324
2014 Alexander S, Kraveka JM, Weitzman S, Lowe E, Smith L, Lynch JC, Chang M, Kinney MC, Perkins SL, Laver J, Gross TG, Weinstein H. Advanced stage anaplastic large cell lymphoma in children and adolescents: results of ANHL0131, a randomized phase III trial of APO versus a modified regimen with vinblastine: a report from the children's oncology group. Pediatric Blood & Cancer. 61: 2236-42. PMID 25156886 DOI: 10.1002/Pbc.25187  0.301
2013 Hou W, Chang MN, Jung SH, Li Y. Designs for randomized phase II clinical trials with two treatment arms. Statistics in Medicine. 32: 4367-79. PMID 23630064 DOI: 10.1002/Sim.5829  0.307
2013 Norkin M, Moreb J, Leather H, Brown RA, Hsu JW, Hiemenz JW, May WS, Chang MN, An Q, Li Y, Cogle CR, Wingard JR. Clinical and Laboratory Factors Influencing The Probability Of Complete Remission In AML Patients With Positive Day 14 Bone Marrows Blood. 122: 1412-1412. DOI: 10.1182/Blood.V122.21.1412.1412  0.326
2012 Urquidi V, Kim J, Chang M, Dai Y, Rosser CJ, Goodison S. CCL18 in a multiplex urine-based assay for the detection of bladder cancer. Plos One. 7. PMID 22629457 DOI: 10.1371/Journal.Pone.0037797  0.301
2012 Chaleff S, Hurwitz CA, Chang M, Dahl G, Alonzo TA, Weinstein H. Phase II study of 2-chlorodeoxyadenosine plus idarubicin for children with acute myeloid leukaemia in first relapse: A Paediatric Oncology Group study British Journal of Haematology. 156: 649-655. PMID 22512017 DOI: 10.1111/J.1365-2141.2011.08976.X  0.336
2012 Chang MN, Shuster JJ, Hou W. Improved two-stage tests for stratified phase II cancer clinical trials. Statistics in Medicine. 31: 1688-98. PMID 22422466 DOI: 10.1002/Sim.5314  0.34
2012 Jung SH, Chang MN, Kang SJ. Phase II cancer clinical trials with heterogeneous patient populations. Journal of Biopharmaceutical Statistics. 22: 312-28. PMID 22251176 DOI: 10.1080/10543406.2010.536873  0.331
2012 Dhanarajan AR, Hsu JW, Wingard JR, Chang MN, Soldevila-Pico C, Rehman S, Baz M, Norkin M. Higher Than Expected Incidence of Chronic Myeloid Leukemia in Solid Organ Transplant Recipients. Blood. 120: 2799-2799. DOI: 10.1182/Blood.V120.21.2799.2799  0.303
2012 Byrne MT, Salmasinia D, Leather H, Davis A, Hsu JW, Wiggins L, Cogle CR, Chang MN, Wingard JR, Moreb JS. Response Post-First Autologous Stem Cell Transplantation for Multiple Myeloma May Identify Patients Who Will Benefit From Tandem Transplants: A Single Center Prospective Phase II Study- an Update Blood. 120: 2023-2023. DOI: 10.1182/Blood.V120.21.2023.2023  0.356
2012 Moreb JS, Salmasinia D, Leather H, Davis A, Hsu J, Wiggins L, Cogle CR, Chang MN, Wingard JR. Abstract 4618: Response post first autologous stem cell transplantation (ASCT) for multiple myeloma identify patients who may benefit from tandem transplants: A single center prospective phase II study Cancer Research. 72: 4618-4618. DOI: 10.1158/1538-7445.Am2012-4618  0.303
2011 Subbiah S, Brown RA, Chang MN, Cogle CR, Hiemenz JW, May WS, Moreb J, Norkin M, Wingard JR, Wirk B, Hsu JW. CECA Results in Improved Response Rates and Ability to Proceed to Stem Cell Transplantation in Adult Refractory or Relapsed Acute Myeloid Leukemia Blood. 118: 4299-4299. DOI: 10.1182/Blood.V118.21.4299.4299  0.339
2011 Chang M, Jung SH, Wu SS. Two-stage designs with additional futility tests for phase ii clinical trials with heterogeneous patient populations Sequential Analysis. 30: 338-349. DOI: 10.1080/07474946.2011.593924  0.317
2010 Chang M. Estimation of multiple response rates in phase II clinical trials with missing observations. Journal of Biopharmaceutical Statistics. 19: 791-802. PMID 20183444 DOI: 10.1080/10543400903105182  0.307
2009 Grobmyer SR, Hemming AW, Harris N, Behrns K, Logan H, Kim RD, Chang M, Cance WG, Hochwald SN. A pilot prospective randomized trial of postoperative epoetin alfa in patients undergoing major operation for upper gastrointestinal malignancy. American Journal of Clinical Oncology. 32: 570-3. PMID 19675446 DOI: 10.1097/Coc.0B013E31819790A8  0.301
2009 Coustan-Smith E, Sandlund JT, Perkins SL, Chen H, Chang M, Abromowitch M, Campana D. Minimal disseminated disease in childhood T-cell lymphoblastic lymphoma: a report from the children's oncology group. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 3533-9. PMID 19546402 DOI: 10.1200/Jco.2008.21.1318  0.308
2009 O'Brien M, Dahl G, Pounds S, Lacayo NJ, Taub J, Chang M, Weinstein HJ, Ravindranath Y, Campana D, Pui C, Rubnitz J. Acute Megakaryoblastic Leukemia (AMKL) in Children without Down Syndrome. Blood. 114: 482-482. DOI: 10.1182/Blood.V114.22.482.482  0.353
2008 Abromowitch M, Termuhlen A, Chang M, Perkins SL, Gross T, Weinstein HJ, Finlay J. High-Dose Methotrexate and Early Intensification of Therapy Do Not Improve 3 Year EFS in Children and Adolescents with Disseminated Lymphoblastic Lymphoma. Results of the Randomized Arms of COG A5971 Blood. 112: 3610-3610. DOI: 10.1182/Blood.V112.11.3610.3610  0.322
2007 Chang MN, Devidas M, Anderson J. One- and two-stage designs for phase II window studies. Statistics in Medicine. 26: 2604-14. PMID 17211853 DOI: 10.1002/Sim.2741  0.304
2007 Hsu JW, Liu H, Jamieson K, Hou W, Chang MN, Ahrens KP, Braylan RC, Wingard JR. Wilm’s Tumor 1 Gene Expression Is a Useful Marker for Minimal Residual Disease in Acute Myeloid Leukemia. Blood. 110: 4240-4240. DOI: 10.1182/Blood.V110.11.4240.4240  0.335
2006 Becton D, Dahl GV, Ravindranath Y, Chang MN, Behm FG, Raimondi SC, Head DR, Stine KC, Lacayo NJ, Sikic BI, Arceci RJ, Weinstein H. Randomized use of cyclosporin A (CsA) to modulate P-glycoprotein in children with AML in remission: Pediatric Oncology Group Study 9421. Blood. 107: 1315-24. PMID 16254147 DOI: 10.1182/Blood-2004-08-3218  0.331
2006 Liu H, Yuan CM, Braylan RC, Chang MN, Wingard JR, Moreb JS. Flow Cytometric Disease Monitoring in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation: A Retrospective Study. Blood. 108: 5014-5014. DOI: 10.1182/Blood.V108.11.5014.5014  0.34
2006 Brown P, McIntyre E, Rau R, Alonzo TA, Gerbing R, Meshinchi S, Lacayo N, Chang M, Arceci R, Small D. Incidence and Clinical Significance of Nucleophosmin Mutations in Childhood AML: A Childrens Oncology Group Study. Blood. 108: 221-221. DOI: 10.1182/Blood.V108.11.221.221  0.319
2006 Champagne MA, Fu C, Chang M, Cooley L, Heerema NA, Wood C, French ME, Smith FO, Bernstein ML. Imatinib in Children with Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia (CP CML): AAML0123 COG Study. Blood. 108: 2140-2140. DOI: 10.1182/Blood.V108.11.2140.2140  0.346
2005 Ravindranath Y, Chang M, Steuber CP, Becton D, Dahl G, Civin C, Camitta B, Carroll A, Raimondi SC, Weinstein HJ. Pediatric Oncology Group (POG) studies of acute myeloid leukemia (AML): A review of four consecutive childhood AML trials conducted between 1981 and 2000 Leukemia. 19: 2101-2116. PMID 16136167 DOI: 10.1038/Sj.Leu.2403927  0.345
2005 Laver JH, Kraveka JM, Hutchison RE, Chang M, Kepner J, Schwenn M, Tarbell N, Desai S, Weitzman S, Weinstein HJ, Murphy SB. Advanced-stage large-cell lymphoma in children and adolescents: results of a randomized trial incorporating intermediate-dose methotrexate and high-dose cytarabine in the maintenance phase of the APO regimen: a Pediatric Oncology Group phase III trial. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 23: 541-7. PMID 15659500 DOI: 10.1200/Jco.2005.11.075  0.338
2004 Chang MN, Shuster JJ, Kepner JL. Sample sizes based on exact unconditional tests for phase II clinical trials with historical controls. Journal of Biopharmaceutical Statistics. 14: 189-200. PMID 15027508 DOI: 10.1081/Bip-120028514  0.3
2004 Loew TW, Gamis A, Smith FO, Massey GV, Woods WG, Hilden JM, Lange B, Alonzo TA, Chang M, Gerbing RB. Down Syndrome Patients with Relapsed Acute Myelogenous Leukemia. Blood. 104: 4526-4526. DOI: 10.1182/Blood.V104.11.4526.4526  0.351
2001 Bell BA, Chang MN, Weinstein HJ. A phase II study of Homoharringtonine for the treatment of children with refractory or recurrent acute myelogenous leukemia: A pediatric oncology group study Medical and Pediatric Oncology. 37: 103-107. PMID 11496347 DOI: 10.1002/Mpo.1177  0.315
2000 Chang M, Raimondi S, Ravindranath Y, Carroll A, Camitta B, Gresik M, Steuber C, Weinstein H. Prognostic factors in children and adolescents with acute myeloid leukemia (excluding children with Down syndrome and acute promyelocytic leukemia): univariate and recursive partitioning analysis of patients treated on Pediatric Oncology Group (POG) Study 8821 Leukemia. 14: 1201-1207. PMID 10914543 DOI: 10.1038/Sj.Leu.2401832  0.326
1987 Chang MN, Therneau TM, Wieand HS, Cha SS. Design for group sequential phase II clinical trials Biometrics. 43: 865-874. PMID 3427171 DOI: 10.2307/2531540  0.304
Show low-probability matches.